4 62 PRO 3/24/2005

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS	9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	10	SEP 22	DIPPR file reloaded
NEWS	11	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS	12	SEP 29	DISSABS now available on STN
NEWS	13	OCT 10	PCTFULL: Two new display fields added

NEWS EXPRESS	OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:25:56 ON 11 OCT 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:26:06 ON 11 OCT 2003

Patel <10/11/2003>

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 OCT 2003 HIGHEST RN 602261-48-3
DICTIONARY FILE UPDATES: 9 OCT 2003 HIGHEST RN 602261-48-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 1008734.1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 08:26:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 85 TO ITERATE

100.0% PROCESSED 85 ITERATIONS 44 ANSWERS
SEARCH TIME: 00.00.01

L2 44 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 08:26:55 ON 11 OCT 2003

FILE COVERS 1907 - 11 Oct 2003 VOL 139 ISS 16
FILE LAST UPDATED: 10 Oct 2003 (20031010/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l2
L3            1 L2

=> s benzofurane and tetrazole
L4            0 BENZOFURANE AND TETRAZOLE

=> s Ip antagonists and AD
L5            0 IP ANTAGONISTS AND AD

=> s IP antagonists
L6            3 IP ANTAGONISTS

=> s l6 and l3
L7            1 L6 AND L3

=> d his

     (FILE 'HOME' ENTERED AT 08:25:56 ON 11 OCT 2003)

     FILE 'REGISTRY' ENTERED AT 08:26:06 ON 11 OCT 2003
L1               STRUCTURE UPLOADED
L2            44 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 08:26:55 ON 11 OCT 2003
L3             1 S L2
L4             0 S BENZOFURANE AND TETRAZOLE
L5             0 S IP ANTAGONISTS AND AD
L6             3 S IP ANTAGONISTS
L7             1 S L6 AND L3

=> d l3 fbib hitstr abs total

L3   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2002:695967  CAPLUS
DN   137:232672
TI   Preparation of substituted benzofuran-2-ylmethyl phenylcarbamates as IP
     antagonists
IN   Lopez-Tapia, Francisco Javier; Nitzan, Dov; O'Yang, Counde
PA   F. Hoffmann-La Roche A.-G., Switz.
SO   PCT Int. Appl., 69 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070500	A1	20020912	WO 2002-EP1943	20020225
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-272872PP	20010302
				US 2001-312559PP	20010815
	US 2002165235	A1	20021107	US 2002-87034	20020301
				US 2001-272872PP	20010302
				US 2001-312559PP	20010815

833P

OS MARPAT 137:232672

IT **458537-01-4P 458537-03-6P 458537-05-8P**
458537-07-0P 458537-09-2P 458537-11-6P
458537-13-8P 458537-14-9P 458537-18-3P
458537-20-7P 458537-22-9P 458537-24-1P
458537-25-2P 458537-27-4P 458537-29-6P
458537-31-0P 458537-32-1P 458537-34-3P
458537-36-5P 458537-38-7P 458537-40-1P
458537-42-3P 458537-44-5P 458537-46-7P
458537-48-9P 458537-50-3P 458537-51-4P
458537-53-6P 458537-55-8P 458537-57-0P
458537-59-2P 458537-60-5P 458537-69-4P
458537-73-0P 458537-74-1P 458537-75-2P
458537-76-3P 458537-77-4P 458537-78-5P
458537-79-6P 458537-80-9P 458537-82-1P
458537-83-2P 458538-18-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted benzofuran-2-ylmethyl phenylcarbamates as IP antagonists)

RN 458537-01-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-03-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-05-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-fluoro-4-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-07-0 CAPLUS
CN Benzoic acid, 2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]-5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 458537-09-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-fluoro-4-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-11-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-13-8 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 458537-14-9 CAPLUS
CN Benzoic acid, 2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-18-3 CAPLUS
CN Benzoic acid, 5-bromo-2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-20-7 CAPLUS
CN Benzoic acid, 5-(methylsulfonyl)-2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-22-9 CAPLUS
CN Benzoic acid, 5-cyano-2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-24-1 CAPLUS
CN Benzoic acid, 2-bromo-6-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-25-2 CAPLUS
CN Benzoic acid, 3,5-dichloro-2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-27-4 CAPLUS
CN Benzoic acid, 5-fluoro-2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-29-6 CAPLUS
CN Benzoic acid, 5-chloro-2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-31-0 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-32-1 CAPLUS
CN Benzoic acid, 5-bromo-2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-34-3 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-6-methyl- (9CI) (CA INDEX NAME)



RN 458537-36-5 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 458537-38-7 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-6-methoxy- (9CI) (CA INDEX NAME)



RN 458537-40-1 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-6-nitro- (9CI) (CA INDEX NAME)



RN 458537-42-3 CAPLUS
CN Benzoic acid, 2-cyano-6-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-44-5 CAPLUS
CN Benzeneacetic acid, 2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-46-7 CAPLUS
CN Benzoic acid, 5-methyl-2-[[[[5-(3-thienyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-48-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-fluoro-4-[[[[5-(3-thienyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-50-3 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-fluoro-4-[[[[5-(3-pyridinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-51-4 CAPLUS
CN Benzoic acid, 5-methyl-2-[[[[5-(3-pyridinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-53-6 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[[5-(3-pyridinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-55-8 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[[5-(5-pyrimidinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-57-0 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[[5-(2-pyridinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-59-2 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[(5-pyrazinyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-60-5 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[[5-(4-pyridazinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-69-4 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 458537-73-0 CAPLUS
CN Carbamic acid, [3-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-, (5-phenyl-2-benzofuranyl)methyl ester (9CI) (CA INDEX NAME)



RN 458537-74-1 CAPLUS
CN Carbamic acid, [3-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-, [5-(3,5-dichlorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-75-2 CAPLUS
CN Carbamic acid, [4'-fluoro-3-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-, [5-(4-fluorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-76-3 CAPLUS
CN Carbamic acid, [3-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-, [5-(4-fluorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-77-4 CAPLUS
CN Carbamic acid, [2-(1H-tetrazol-5-yl)phenyl]-, [5-(4-fluorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-78-5 CAPLUS
CN Carbamic acid, [4-bromo-2-(1H-tetrazol-5-yl)phenyl]-, [5-(4-fluorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-79-6 CAPLUS
CN Carbamic acid, [4-fluoro-2-(1H-tetrazol-5-yl)phenyl]-, [5-(4-fluorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-80-9 CAPLUS
CN Carbamic acid, [4-bromo-2-(1H-tetrazol-5-yl)phenyl]-, (5-phenyl-2-benzofuranyl)methyl ester (9CI) (CA INDEX NAME)



RN 458537-82-1 CAPLUS
CN Carbamic acid, [2-(1H-tetrazol-5-yl)phenyl]-, (5-phenyl-2-benzofuranyl)methyl ester (9CI) (CA INDEX NAME)



RN 458537-83-2 CAPLUS
CN Benzoic acid, 2-amino-6-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)





RN 458538-18-6 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



GI



II



III



IV



V

AB The title alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl Ph derivs. G1CH2OCONHG2 [I; G1 = II-IV (wherein A = (un)substituted Ph, pyridyl, pyrimidinyl, etc.); G2 = (un)substituted

2-carboxyphenyl, 3-carboxybiphenyl-4-yl, 3-(1H-tetrazol-5-yl)biphenyl-4-yl, etc.] which are generally IP receptor antagonists useful in treating disorders of the urinary tract, pain, inflammation, respiratory states such as allergies and asthma, edema formation or hypotensive vascular diseases, were prepd. and formulated. Thus, treating Me 2-amino-5-phenylbenzoate (prepn. given) with phosgene followed by addn. of (5-phenylbenzofuran-2-yl)methanol (prepn. given), and hydrolysis of the resulting Me ester afforded the acid V which showed pKi of 7.6 in in vitro human platelet receptor binding assay.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 16 fbib hitstr abstotal
'ABSTOTAL' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields

```
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs
```

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

```
ENTER DISPLAY FORMAT (BIB):bibn
'BIBN' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
```

The following are valid formats:

```
ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
```

```
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):BIB

L6   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2002:695978  CAPLUS
DN   137:232662
TI   Preparation of alkoxycarbonylamino heteroaryl carboxylic acids as
     IP antagonists
IN   Lopez-Tapia, Francisco Javier; Nitzan, Dov; O'Yang, Counde
PA   F. Hoffmann-La Roche A.-G., Switz.
SO   PCT Int. Appl., 45 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 2002070514      A1   20020912      WO 2002-EP1942   20020225
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
--->US 2002169171      A1   20021114      US 2002-86615    20020301
--->US 6569860         B2   20030527
PRAI US 2001-272849P   P    20010302
OS   MARPAT 137:232662
RE.CNT  4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d l6 fbib hitstr abs total

L6   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
```

AN 2002:695978 CAPLUS
DN 137:232662
TI Preparation of alkoxycarbonylamino heteroaryl carboxylic acids as **IP antagonists**
IN Lopez-Tapia, Francisco Javier; Nitzan, Dov; O'Yang, Counde
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002070514	A1	20020912	WO 2002-EP1942	20020225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-272849PP	20010302
US 2002169171	A1	20021114	US 2002-86615	20020301
US 6569860	B2	20030527		
			US 2001-272849PP	20010302

OS MARPAT 137:232662
GI



II



III

AB The title compds. G1CH2OCONHG2 [I; G1 = II, III (wherein A = (un)substituted Ph, pyridyl, pyrimidinyl, thienyl); G2 = (un)substituted 4-carboxypyrimidin-5-yl, 4-carboxypyrazol-3-yl, 4-carboxypyridin-3-yl, etc.] which are IP receptor antagonists, useful in treating disorders of the urinary tract, pain, inflammation, respiratory states such as allergies and asthma, edema formation or hypotensive vascular diseases, were prepd. and formulated. Thus, treating Et 3-aminopyridine-4-carboxylate.HCl with phosgene followed by addn. of (5-phenylbenzofuran-2-yl)methanol (prepn. given), and hydrolysis of the ester afforded I [G1 = II; A = Ph; G2 = 4-carboxypyridin-3-yl] which showed pKi of 6.7 in in vitro human platelet IP receptor binding assay.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:695967 CAPLUS
DN 137:232672
TI Preparation of substituted benzofuran-2-ylmethyl phenylcarbamates as **IP antagonists**
IN Lopez-Tapia, Francisco Javier; Nitzan, Dov; O'Yang, Counde

PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002070500	A1	20020912	WO 2002-EP1943	20020225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			US 2001-272872PP	20010302
			US 2001-312559PP	20010815
US 2002165235	A1	20021107	US 2002-87034	20020301
			US 2001-272872PP	20010302
			US 2001-312559PP	20010815

OS MARPAT 137:232672
GI



II



III



IV



V

AB The title alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl Ph derivs. G1CH2OCONHG2 [I; G1 = II-IV (wherein A = (un)substituted Ph, pyridyl, pyrimidinyl, etc.); G2 = (un)substituted 2-carboxyphenyl, 3-carboxybiphenyl-4-yl, 3-(1H-tetrazol-5-yl)biphenyl-4-

yl, etc.] which are generally IP receptor antagonists useful in treating disorders of the urinary tract, pain, inflammation, respiratory states such as allergies and asthma, edema formation or hypotensive vascular diseases, were prepd. and formulated. Thus, treating Me 2-amino-5-phenylbenzoate (prepn. given) with phosgene followed by addn. of (5-phenylbenzofuran-2-yl)methanol (prepn. given), and hydrolysis of the resulting Me ester afforded the acid V which showed pKi of 7.6 in in vitro human platelet receptor binding assay.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:693269 CAPLUS
DN 135:257467
TI Preparation of N-(arylmethoxycarbonyl)phenylalanine derivatives as **IP antagonists**
IN Cournoyer, Richard Leo; Keitz, Paul Francis; Lowrie, Lee Edwin, Jr.; Muehldorf, Alexander Victor; O'Yang, Counde; Yasuda, Dennis Mitsugu
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001068591	A1	20010920	WO 2001-EP2597	20010308
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			US 2000-190129PP	20000316
			US 2000-247129PP	20001110
BR 2001009235	A	20021217	BR 2001-9235	20010308
			US 2000-190129PP	20000316
			US 2000-247129PP	20001110
			WO 2001-EP2597 W	20010308
EP 1265853	A1	20021218	EP 2001-925395	20010308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			US 2000-190129PP	20000316
			US 2000-247129PP	20001110
			WO 2001-EP2597 W	20010308
JP 2003527368	T2	20030916	JP 2001-567688	20010308
			US 2000-190129PP	20000316
			US 2000-247129PP	20001110
			WO 2001-EP2597 W	20010308
→ US 2001056100	A1	20011227	US 2001-810436	20010314
			US 2000-190129PP	20000316
			US 2000-247129PP	20001110
NO 2002004387	A	20021021	NO 2002-4387	20020913
			US 2000-190129PP	20000316
			US 2000-247129PP	20001110

09/810436

WO 2001-EP2597 W 20010308

OS MARPAT 135:257467
GI



I



II

AB Title compds. I [wherein R1, R2, and R3 = independently (un)substituted (hetero)aryl; R4 = COOH or tetrazolyl; A = single bond, O(CH2)q, S(CH2)q, NR'(CH2)q, (CH2)qO, O(CH2)qO, (CH2)qO(CH2)q, (CH2)nCO(CH2)q, CONH, (CH2)q, CH:CH, or C.tplbond.C; R' = H or alkyl; B = (CH2)r, CH2O, CH2OCH2, or CH2NH; m, q, and r = independently 1-3; n and p = independently 0-3; or individual isomers, racemic or nonracemic mixts. of isomers, or pharmaceutically acceptable salts or solvates thereof] were prepd. as prostaglandin IP receptor antagonists. For example, 4-vinylbenzoic acid was esterified with MeOH (97.4%). The ester was hydroborated with 9-BBN in THF and oxidized with alk. HOOH to give 4-(2-hydroxyethyl)benzoic acid Me ester (64.7%). Etherification with PhOH in the presence of PPh3 and diEt azodicarboxylate in THF (16.8%), followed by redn. with LiAlH4, condensation with Me (R)-2-isocyanato-3-phenylpropionate, and hydrolysis, afforded II. The latter showed affinity toward the human platelet IP receptor with a Ki value of 6.6. I are useful for the treatment of inflammatory conditions, pain, bladder disorders, hypotensive vascular diseases, and respiratory diseases, such as allergies and asthma (no data).

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l7 fbib hitstr abs total

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:695967 CAPLUS
DN 137:232672
TI Preparation of substituted benzofuran-2-ylmethyl phenylcarbamates as **IP antagonists**
IN Lopez-Tapia, Francisco Javier; Nitzan, Dov; O'Yang, Counde
PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002070500	A1	20020912	WO 2002-EP1943	20020225

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-272872PP	20010302
			US 2001-312559PP	20010815
US 2002165235	A1	20021107	US 2002-87034	20020301
			US 2001-272872PP	20010302
			US 2001-312559PP	20010815

OS MARPAT 137:232672
IT **458537-01-4P 458537-03-6P 458537-05-8P**
458537-07-0P 458537-09-2P 458537-11-6P
458537-13-8P 458537-14-9P 458537-18-3P
458537-20-7P 458537-22-9P 458537-24-1P
458537-25-2P 458537-27-4P 458537-29-6P
458537-31-0P 458537-32-1P 458537-34-3P
458537-36-5P 458537-38-7P 458537-40-1P
458537-42-3P 458537-44-5P 458537-46-7P
458537-48-9P 458537-50-3P 458537-51-4P
458537-53-6P 458537-55-8P 458537-57-0P
458537-59-2P 458537-60-5P 458537-69-4P
458537-73-0P 458537-74-1P 458537-75-2P
458537-76-3P 458537-77-4P 458537-78-5P
458537-79-6P 458537-80-9P 458537-82-1P
458537-83-2P 458538-18-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted benzofuran-2-ylmethyl phenylcarbamates as **IP antagonists**)
RN 458537-01-4 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-03-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3-[[[(5-phenyl-2-

benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-05-8 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-fluoro-4-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-07-0 CAPLUS
CN Benzoic acid, 2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]-5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 458537-09-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-fluoro-4-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-11-6 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-13-8 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 458537-14-9 CAPLUS
CN Benzoic acid, 2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-18-3 CAPLUS
CN Benzoic acid, 5-bromo-2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-20-7 CAPLUS
CN Benzoic acid, 5-(methylsulfonyl)-2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-22-9 CAPLUS
CN Benzoic acid, 5-cyano-2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-24-1 CAPLUS
CN Benzoic acid, 2-bromo-6-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-25-2 CAPLUS
CN Benzoic acid, 3,5-dichloro-2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-27-4 CAPLUS
CN Benzoic acid, 5-fluoro-2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-29-6 CAPLUS
CN Benzoic acid, 5-chloro-2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-31-0 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-32-1 CAPLUS
CN Benzoic acid, 5-bromo-2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-34-3 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-6-methyl- (9CI) (CA INDEX NAME)



RN 458537-36-5 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 458537-38-7 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-6-methoxy- (9CI) (CA INDEX NAME)



RN 458537-40-1 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-6-nitro- (9CI) (CA INDEX NAME)



RN 458537-42-3 CAPLUS
CN Benzoic acid, 2-cyano-6-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-44-5 CAPLUS
CN Benzeneacetic acid, 2-[[[(5-phenyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-46-7 CAPLUS
CN Benzoic acid, 5-methyl-2-[[[[5-(3-thienyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-48-9 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-fluoro-4-[[[[5-(3-thienyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-50-3 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-fluoro-4-[[[[5-(3-pyridinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-51-4 CAPLUS
CN Benzoic acid, 5-methyl-2-[[[[5-(3-pyridinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-53-6 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[[5-(3-pyridinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-55-8 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[[5-(5-pyrimidinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-57-0 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[[5-(2-pyridinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-59-2 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[(5-pyrazinyl-2-benzofuranyl)methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-60-5 CAPLUS
CN Benzoic acid, 2-chloro-6-[[[[5-(4-pyridazinyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 458537-69-4 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 458537-73-0 CAPLUS
CN Carbamic acid, [3-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-, (5-phenyl-2-benzofuranyl)methyl ester (9CI) (CA INDEX NAME)



RN 458537-74-1 CAPLUS
CN Carbamic acid, [3-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-, [5-(3,5-dichlorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-75-2 CAPLUS
CN Carbamic acid, [4'-fluoro-3-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-, [5-(4-fluorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-76-3 CAPLUS
CN Carbamic acid, [3-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-, [5-(4-fluorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-77-4 CAPLUS
CN Carbamic acid, [2-(1H-tetrazol-5-yl)phenyl]-, [5-(4-fluorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-78-5 CAPLUS
CN Carbamic acid, [4-bromo-2-(1H-tetrazol-5-yl)phenyl]-, [5-(4-fluorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-79-6 CAPLUS
CN Carbamic acid, [4-fluoro-2-(1H-tetrazol-5-yl)phenyl]-, [5-(4-fluorophenyl)-2-benzofuranyl]methyl ester (9CI) (CA INDEX NAME)



RN 458537-80-9 CAPLUS
CN Carbamic acid, [4-bromo-2-(1H-tetrazol-5-yl)phenyl]-, (5-phenyl-2-benzofuranyl)methyl ester (9CI) (CA INDEX NAME)



RN 458537-82-1 CAPLUS
CN Carbamic acid, [2-(1H-tetrazol-5-yl)phenyl]-, (5-phenyl-2-benzofuranyl)methyl ester (9CI) (CA INDEX NAME)



RN 458537-83-2 CAPLUS
CN Benzoic acid, 2-amino-6-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]- (9CI) (CA INDEX NAME)





RN 458538-18-6 CAPLUS
CN Benzoic acid, 2-[[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]amino]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



GI



II



III



IV



V

AB The title alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl Ph derivs. G1CH2OCONHG2 [I; G1 = II-IV (wherein A = (un)substituted Ph, pyridyl, pyrimidinyl, etc.); G2 = (un)substituted

2-carboxyphenyl, 3-carboxybiphenyl-4-yl, 3-(1H-tetrazol-5-yl)biphenyl-4-yl, etc.] which are generally IP receptor antagonists useful in treating disorders of the urinary tract, pain, inflammation, respiratory states such as allergies and asthma, edema formation or hypotensive vascular diseases, were prepd. and formulated. Thus, treating Me 2-amino-5-phenylbenzoate (prepn. given) with phosgene followed by addn. of (5-phenylbenzofuran-2-yl)methanol (prepn. given), and hydrolysis of the resulting Me ester afforded the acid V which showed pKi of 7.6 in in vitro human platelet receptor binding assay.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	32.30	180.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.26	-3.26

STN INTERNATIONAL LOGOFF AT 08:30:59 ON 11 OCT 2003

L Number	Hits	Search Text	DB	Time stamp
1	4983	("514/183,381,449,467,469").CCLS	USPAT	2003/10/11 11:10
2	984	("548/250,252").CCLS	USPAT	2003/10/11 11:10
3	1592	("549/432,434,462,491,497").CCLS	USPAT	2003/10/11 11:10
4	18	(("514/183,381,449,467,469").CCLS) and (("548/250,252").CCLS) and (("549/432,434,462,491,497").CCLS)	USPAT	2003/10/11 11:11

L Number	Hits	Search Text	DB	Time stamp
1	4983	("514/183,381,449,467,469").CCLS	USPAT	2003/10/11 11:10
2	984	("548/250,252").CCLS	USPAT	2003/10/11 11:10
3	1592	("549/432,434,462,491,497").CCLS	USPAT	2003/10/11 11:10
4	18	(("514/183,381,449,467,469").CCLS) and (("548/250,252").CCLS) and (("549/432,434,462,491,497").CCLS)	USPAT	2003/10/11 11:11

L Number	Hits	Search Text	DB	Time stamp
1	2336	Prostaglandin and Pain	USPAT	2003/10/11 09:39
2	3353	Prostaglandin and inflammation	USPAT	2003/10/11 09:39
3	37536	Prostaglandin and urinary tract	USPAT	2003/10/11 09:40
4	753	(Prostaglandin and Pain) and (Prostaglandin and inflammation) and (Prostaglandin and urinary tract)	USPAT	2003/10/11 09:40
5	52	((Prostaglandin and Pain) and (Prostaglandin and inflammation) and (Prostaglandin and urinary tract)) and benzofuran	USPAT	2003/10/11 09:40
6	43	((Prostaglandin and Pain) and (Prostaglandin and inflammation) and (Prostaglandin and urinary tract)) and tetrazole	USPAT	2003/10/11 09:40
7	10	(((Prostaglandin and Pain) and (Prostaglandin and inflammation) and (Prostaglandin and urinary tract)) and benzofuran) and (((Prostaglandin and Pain) and (Prostaglandin and inflammation) and (Prostaglandin and urinary tract)) and tetrazole)	USPAT	2003/10/11 09:40

L Number	Hits	Search Text	DB	Time stamp
1	2336	Prostaglandin and Pain	USPAT	2003/10/11 09:39
2	3353	Prostaglandin and inflammation	USPAT	2003/10/11 09:39
3	37536	Prostaglandin and urinary tract	USPAT	2003/10/11 09:40
4	753	(Prostaglandin and Pain) and (Prostaglandin and inflammation) and (Prostaglandin and urinary tract)	USPAT	2003/10/11 09:40
5	52	((Prostaglandin and Pain) and (Prostaglandin and inflammation) and (Prostaglandin and urinary tract)) and benzofuran	USPAT	2003/10/11 09:40
6	43	((Prostaglandin and Pain) and (Prostaglandin and inflammation) and (Prostaglandin and urinary tract)) and tetrazole	USPAT	2003/10/11 09:40
7	10	(((Prostaglandin and Pain) and (Prostaglandin and inflammation) and (Prostaglandin and urinary tract)) and benzofuran) and (((Prostaglandin and Pain) and (Prostaglandin and inflammation) and (Prostaglandin and urinary tract)) and tetrazole)	USPAT	2003/10/11 09:40